Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer
Erasca (ERAS) and Bristol Myers Squibb (BMY) will collaborate on a Phase 1/2 trial to study ERAS-0015 and navlimetostat in MTAP-deleted pancreatic cancer. ERAS-0015 targets RAS, while navlimetostat inhibits PRMT5. Erasca will supply the drug, and BMY will sponsor the study. ERAS stock closed at $13.89, up 3.05% in after-hours trading.
How this was made

The 30-second read
Why it matters
The announcement provides Erasca with validation and potential funding, while BMY expands its early‑stage pipeline. Both stocks may experience short‑term price bumps, but long‑term impact depends on trial outcomes.
Market read
First‑report of a biotech‑big‑pharma partnership, offering a fresh catalyst for both ERAS and BMY, with modest but positive market implications.
What to watch
The trial targets a rare MTAP‑deleted subset, limiting market size; regulatory timelines remain uncertain.
Background
Erasca is a micro‑cap biotech focused on pan‑RAS molecular glues. Bristol Myers Squibb is a large, diversified oncology player. The collaboration combines two investigational agents for a specific genetic subtype of pancreatic cancer.
Ticker impact
Erasca announced a new Phase 1/2 trial partnership with Bristol Myers Squibb to test its pan‑RAS molecular glue ERAS‑0015 in MTAP‑deleted pancreatic cancer.
upward pressure as investors price in potential clinical success and partnership validation
First‑report partnership with a large pharma partner (BMY) adds credibility and may accelerate development, a material catalyst for a micro‑cap biotech.
Bristol Myers Squibb will sponsor a Phase 1/2 study combining its PRMT5 inhibitor navlimetostat with Erasca's ERAS‑0015 for MTAP‑deleted pancreatic cancer.
slight upward pressure as the market sees expansion of BMY's oncology portfolio
While BMY is a large, diversified company, new early‑stage oncology collaborations are generally welcomed but have limited immediate impact.
Market effects
Highlights growing interest in pan‑RAS and PRMT5 inhibition strategies, potentially boosting biotech and oncology sector sentiment.
U.S. biotech and pharma stocks may see modest gains as investors reassess pipeline collaborations.
Adds to the global trend of big pharma partnering with niche biotech firms to de‑risk early‑stage oncology programs.
Counterpoint
Early‑stage trial data may be disappointing; partnership could dilute Erasca's valuation if milestones are missed.
Key entities
- companyErasca, Inc.
Developer of ERAS‑0015, a pan‑RAS molecular glue.
- companyBristol Myers Squibb
Pharma giant sponsoring the combination trial with its PRMT5 inhibitor navlimetostat.



